Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

被引：41
|
作者：
Doebele, R. [1 ]
Ahn, M. [2 ]
Siena, S. [3 ,4 ]
Drilon, A. [5 ]
Krebs, M. [6 ]
Lin, C. [7 ]
De Braud, F. [8 ]
John, T. [9 ]
Tan, D. [10 ]
Seto, T. [11 ]
Dziadziuszko, R. [12 ]
Arkenau, H. [13 ]
Barlesi, F. [14 ]
Rolfo, C. [15 ]
Wolf, J. [16 ]
Chow-Maneval, E. [17 ]
Multani, P. [17 ]
Cui, N. [18 ]
Riehl, T. [18 ]
Cho, B. C. [9 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Seoul, South Korea
[3] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy
[4] Univ Milan, Milan, Italy
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA
[6] Univ Manchester, Manchester, Lancs, England
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[9] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[10] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[11] Natl Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[12] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland
[13] Sarah Cannon Res Inst, London, England
[14] Aix Marseille Univ, AP HM, Marseille, France
[15] Antwerp Univ Hosp, Oncol Dept, Phase 1 Early Clin Trials Unit, Antwerp, Belgium
[16] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Cologne, Germany
[17] Ignyta Inc, San Diego, CA USA
[18] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; entrectinib; ROS1 gene fusion;
D O I：
10.1016/j.jtho.2018.08.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA02.01
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [21] Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib
    Dogan, Izzet
    Khanmammadov, Nijat
    Paksoy, Nail
    Ferhatoglu, Ferhat
    Aydin, Esra
    Vatansever, Sezai
    Aydine, Adnan
    TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY, 2022, 37 (04): : 413 - 418
  • [22] Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence
    Nadal, Ernest
    Rifi, Nada
    Kane, Sarah
    Mbacke, Sokhna
    Starkman, Lindsey
    Suero, Beatrice
    Le, Hannah
    Samjoo, Imtiaz A.
    LUNG CANCER, 2024, 192
  • [23] Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
    Liu, Dazhi
    Offin, Michael
    Harnicar, Stephen
    Li, Bob T.
    Drilon, Alexander
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2018, 14 : 1247 - 1252
  • [24] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Ming Gao
    Xia Zhang
    Huan Yan
    Decong Sun
    Xuejiao Yang
    Fang Yuan
    Yanfang Ju
    Lijie Wang
    Jinliang Wang
    Wei Zhao
    Dong Zhang
    Lin Li
    Xiaoyun Xu
    Junxun Ma
    Yi Hu
    Xiaotao Zhang
    Supportive Care in Cancer, 2023, 31
  • [25] Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
    Gao, Ming
    Zhang, Xia
    Yan, Huan
    Sun, Decong
    Yang, Xuejiao
    Yuan, Fang
    Ju, Yanfang
    Wang, Lijie
    Wang, Jinliang
    Zhao, Wei
    Zhang, Dong
    Li, Lin
    Xu, Xiaoyun
    Ma, Junxun
    Hu, Yi
    Zhang, Xiaotao
    SUPPORTIVE CARE IN CANCER, 2023, 31 (12)
  • [26] Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer
    Wong, Wenjing
    Sun, Ping
    Mu, Zhengbin
    Liu, Jiannan
    Yu, Caiyan
    Liu, Aina
    ANTICANCER RESEARCH, 2017, 37 (08) : 4687 - 4691
  • [27] CRIZOTINIB THERAPY FOR PATIENTS WITH ADVANCED ROS1-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC)
    Ou, Sai-Hong I.
    Kim, Dong-Wan
    Camidge, D. Ross
    Riely, Gregory
    Salgia, Ravi
    Shapiro, Geoffrey
    Solomon, Ben
    Engelman, Jeffrey A.
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Tye, Lesley
    Wilner, Keith
    Usari, Tiziana
    Varella-Garcia, Marileila
    Bergethon, Kristin
    Iafrate, A. J.
    Shaw, Alice T.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S295 - S295
  • [28] CLINICAL ACTIVITY OF CRIZOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING THE ROS1 GENE REARRANGEMENT
    Ou, Sai-hong I.
    Bang, Y-j
    Camidge, D. R.
    Engelman, J. A.
    Clark, J. W.
    Tye, L.
    Wilner, Keith
    Stephenson, P.
    Chung, D. H.
    Varella-Garcia, M.
    Iafrate, A. J.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S455 - S455
  • [29] PHYSICAL TARGETING OF LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): PROTON THERAPY
    Cox, James D.
    Quynh Nguyen
    Allen, Pamela
    Ly, Ngoc B.
    Gomez, Daniel
    Chang, Joe
    Liao, Zhongxing
    Tsao, Anne
    Komaki, Ritsuko
    Lu, Charles
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S597 - S597
  • [30] Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
    Zhong, Yuejiao
    Wei, Qiang
    Lu, You
    Tang, Xiuliang
    Wang, Zhongqiu
    Chen, Lingxiang
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6016 - 6022
12345